Next-generation sequencing (NGS) is a disruptive technological development in the life sciences industry, which has paved the path for the development of several breakthrough medical procedures that are aimed to address the primary concern for global health. The development of next-generation sequencing technology has introduced fundamental changes in the process of genome sequencing in order to reduce cost and turnaround time. With its immense potential, NGS enables the understanding of the threat that a particular disease can pose to an individual and aid in the development of precise curative medical procedures. The current study aims to assess the global NGS sample preparation market by focusing on products (consumables, standalone automation instruments, automated workstation, accessories, and components) catering to end users, including hospitals and clinics, academic and research institutions, pharmaceutical and biotechnology companies, other end users (non-profit organizations, reference laboratories, and others). The current market for NGS sample preparation is majorly dominated by manufacturers and service providers such as Aurora Biomed, Inc., Bio-Rad Laboratories, Danaher Corporation, BGI, Eppendorf AG, F. Hoffmann-La Roche Ltd., Hamilton Company, Illumina, Inc., New England Biolabs, Inc., Oxford Nanopore Technologies, Ltd., QIAGEN, PerkinElmer, Inc., and Promega Corporation.

1. Markets

2. industry Insights

3. Competitive Landscape

4. Products

5. Workflow 

6. Therapeutic 

7. Application 

8. End-User